Haemochromatosis HFE gene polymorphisms as potential modifiers of hereditary nonpolyposis colorectal cancer risk and onset age

International Journal of Cancer

Volumn 125, Issue 1, 2009, Pages 78-83

  Shi, Zumin ^a   Johnstone, Daniel ^a,b   Talseth Palmer, Bente A ^b,c   Evans, Tiffany Jane ^c   Spigelman, Allan D ^d   Groombridge, Claire ^e   Milward, Elizabeth A ^a,b   Olynyk, John K ^f   Suchy, Janina ^g   Kurzawski, Grzegorz ^g   Lubinski, Jan ^g   Scott, Rodney J ^b,c,h  

^a UNIVERSITY OF NEWCASTLE   (Australia)

^b UNIVERSITY OF NEWCASTLE   (Australia)

^c HUNTER MEDICAL RESEARCH INSTITUTE   (Australia)

^d ST VINCENT S HOSPITAL   (Australia)

^e Hunter Family Cancer Service   (Australia)

^f UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^g POMERANIAN MEDICAL UNIVERSITY   (Poland)

^h JOHN HUNTER HOSPITAL   (Australia)

Author keywords

Colorectal cancer; Haemochromatosis; HFE; HNPCC; Polymorphisms

Indexed keywords

ADOLESCENT; ADULT; AGED; ARTICLE; AUSTRALIA; CANCER RISK; COLORECTAL CANCER; COMPARATIVE STUDY; CONTROLLED STUDY; FEMALE; GENE; GENE EXPRESSION; GENE MUTATION; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; HEMOCHROMATOSIS; HETEROZYGOSITY; HETEROZYGOTE; HFE GENE; HOMOZYGOSITY; HOMOZYGOTE; HUMAN; LOG RANK TEST; MAJOR CLINICAL STUDY; MALE; ONSET AGE; PHENOTYPE; POLAND; PRIORITY JOURNAL; RANK SUM TEST; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; WILD TYPE; COLORECTAL TUMOR; GENETICS; SURVIVAL RATE;

HFE PROTEIN, HUMAN; HLA ANTIGEN CLASS 1; MEMBRANE PROTEIN;

ADULT; AGE OF ONSET; AUSTRALIA; COLORECTAL NEOPLASMS, HEREDITARY NONPOLYPOSIS; FEMALE; GENOTYPE; HEMOCHROMATOSIS; HETEROZYGOTE; HISTOCOMPATIBILITY ANTIGENS CLASS I; HOMOZYGOTE; HUMANS; MALE; MEMBRANE PROTEINS; POLAND; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK FACTORS; SURVIVAL RATE;

EID: 66149146661     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.24304     Document Type: Article

References (47)

1. Bronner CE, Baker SM, Morrison PT, Warren G, Smith LG, Lescoe MK, Kane M, Earabino C, Lipford J, Lindblom A, Tannergard P, Bollag RJ, et al. Mutation in the DNA mismatch repair gene homologue hMLH1 is associated with hereditary non-polyposis colon cancer. Nature 1994;368:258-61.
2. Leach FS, Nicolaides NC, Papadopoulos N, Liu B, Jen J, Parsons R, Peltomaki P, Sistonen P, Aaltonen LA, Nystrom-Lahti M, Guan X-Y, Zhang J, et al. Mutations of a mutS homolog in hereditary nonpolyposis colorectal cancer. Cell 1993;75:1215-25.
3. Peltomaki P. DNA mismatch repair and cancer. Mutat Res 2001;488:77-85.
4. Peltomaki P, Vasen HF. Mutations predisposing to hereditary nonpolyposis colorectal cancer: database and results of a collaborative study. The International Collaborative Group on Hereditary Nonpolyposis Colorectal Cancer. Gastroenterology 1997;113:1146-58.
5. Lawes DA, SenGupta SB, Boulos PB. Pathogenesis and clinical management of hereditary non-polyposis colorectal cancer. Br J Surg 2002;89:1357-69.
6. Scott RJ, McPhillips M, Meldrum CJ, Fitzgerald PE, Adams K, Spigelman AD, du Sart D, Tucker K, Kirk J. Hereditary nonpolyposis colorectal cancer in 95 families: differences and similarities between mutation-positive and mutation-negative kindreds. Am J Hum Genet 2001;68:118-27.
7. Felix R, Bodmer W, Fearnhead NS, van der Merwe L, Goldberg P, Ramesar RS. GSTM1 and GSTT1 polymorphisms as modifiers of age at diagnosis of hereditary nonpolyposis colorectal cancer (HNPCC) in a homogeneous cohort of individuals carrying a single predisposing mutation. Mutat Res 2006;602:175-81.
8. Heinimann K, Scott RJ, Chappuis P, Weber W, Muller H, Dobbie Z, Hutter P. N-acetyltransferase 2 influences cancer prevalence in hMLH1/hMSH2 mutation carriers. Cancer Res 1999;59:3038-40.
9. Talseth BA, Ashton KA, Meldrum C, Suchy J, Kurzawski G, Lubinski J, Scott RJ. Aurora-A and Cyclin D1 polymorphisms and the age of onset of colorectal cancer in hereditary nonpolyposis colorectal cancer. Int J Cancer 2008;122:1273-7.
10. Talseth BA, Meldrum C, Suchy J, Kurzawski G, Lubinski J, Scott RJ. Genetic polymorphisms in xenobiotic clearance genes and their influence on disease expression in hereditary nonpolyposis colorectal cancer patients. Cancer Epidemiol Biomarkers Prev 2006;15:2307-10.
11. Zecevic M, Amos CI, Gu X, Campos IM, Jones JS, Lynch PM, Rodriguez-Bigas MA, Frazier ML. IGF1 gene polymorphism and risk for hereditary nonpolyposis colorectal cancer. J Natl Cancer Inst 2006;98:139-43.
12. Kabat GC, Miller AB, Jain M, Rohan TE. A cohort study of dietary iron and heme iron intake and risk of colorectal cancer in women. Br J Cancer 2007;97:118-22.
13. Kato I, Dnistrian AM, Schwartz M, Toniolo P, Koenig K, Shore RE, Zeleniuch-Jacquotte A, Akhmedkhanov A, Riboli E. Iron intake, body iron stores and colorectal cancer risk in women: a nested case-control study. Int J Cancer 1999;80:693-8.
14. Larsson SC, Rafter J, Holmberg L, Bergkvist L, Wolk A. Red meat consumption and risk of cancers of the proximal colon, distal colon and rectum: the Swedish Mammography Cohort. Int J Cancer 2005;113:829-34.
15. Nelson RL. Iron and colorectal cancer risk: human studies. Nutr Rev 2001;59:140-8.
16. Norat T, Riboli E. Meat consumption and colorectal cancer: a review of epidemiologic evidence. Nutr Rev 2001;59:37-47.
17. Beutler E. Hemochromatosis: genetics and pathophysiology. Annu Rev Med 2006;57:331-47.
18. Camaschella C. Understanding iron homeostasis through genetic analysis of hemochromatosis and related disorders. Blood 2005;106:3710-7.
19. Pietrangelo A. Hereditary hemochromatosis. Ann Rev Nutr 2006;26:251-70.
20. Adams PC, Reboussin DM, Barton JC, McLaren CE, Eckfeldt JH, McLaren GD, Dawkins FW, Acton RT, Harris EL, Gordeuk VR, Leiendecker-Foster C, Speechley M, et al. Hemochromatosis and iron-overload screening in a racially diverse population. N Engl J Med 2005;352:1769-78.
21. Ellervik C, Birgens H, Tybjaerg-Hansen A, Nordestgaard BG. Hemochromatosis genotypes and risk of 31 disease endpoints: meta-analyses including 66,000 cases and 226,000 controls. Hepatology 2007;46:1071-80.
22. Olynyk JK, Cullen DJ, Aquilia S, Rossi E, Summerville L, Powell LW. A population-based study of the clinical expression of the hemochromatosis gene. N Engl J Med 1999;341:718-24.
23. Whitlock EP, Garlitz BA, Harris EL, Beil TL, Smith PR. Screening for hereditary hemochromatosis: a systematic review for the U.S. Preventive Services Task Force. Ann Intern Med 2006;145:209-23.
24. Chua AC, Graham RM, Trinder D, Olynyk JK. The regulation of cellular iron metabolism. Crit Rev Clin Lab Sci 2007;44:413-59.
25. Gochee PA, Powell LW, Cullen DJ, Du Sart D, Rossi E, Olynyk JK. A population-based study of the biochemical and clinical expression of the H63D hemochromatosis mutation. Gastroenterology 2002;122:646-51.
26. Jackson HA, Carter K, Darke C, Guttridge MG, Ravine D, Hutton RD, Napier JA, Worwood M. HFE mutations, iron deficiency and overload in 10,500 blood donors. Bt J Haematol 2001;114:474-84.
27. Milman N, Pedersen P, Ovesen L, Melsen GV, Fenger K. Frequency of the C282Y and H63D mutations of the hemochromatosis gene (HFE) in 2501 ethnic Danes. Ann Hematol 2004;83:654-7.
28. Steinberg KK, Cogswell ME, Chang JC, Caudill SP, McQuillan GM, Bowman BA, Grummer-Strawn LM, Sampson EJ, Khoury MJ, Gallagher ML. Prevalence of C282Y and H63D mutations in the hemochromatosis (HFE) gene in the United States. JAMA 2001;285:2216-22.
29. Allen KJ, Gurrin LC, Constantine CC, Osborne NJ, Delatycki MB, Nicoll AJ, McLaren CE, Bahlo M, Nisselle AE, Vulpe CD, Anderson GJ, Southey MC, et al. Iron-overload-related disease in HFE hereditary hemochromatosis. N Engl J Med 2008;358:221-30.
30. Osborne NJ, Gurrin LC, Allen KJ, Constantine CC, Delatycki MB, Nisselle AE, Fletcher AR, McLaren CE, English DR, Hopper JL, Giles GG, Olynyk J, et al. Homozygosity for the C282Y mutation in the HFE gene is associated with increased risk of colorectal and breast cancer in Australian population. Am J Hematol 2007;82:575.
31. Chan AT, Ma J, Tranah GJ, Giovannucci EL, Rifai N, Hunter DJ, Fuchs CS. Hemochromatosis gene mutations, body iron stores, dietary iron, and risk of colorectal adenoma in women. J Natl Cancer Inst 2005;97:917-26.
32. Macdonald GA, Tarish J, Whitehall VJ, McCann SJ, Mellick GD, Buttenshaw RL, Johnson AG, Young J, Leggett BA. No evidence of increased risk of colorectal cancer in individuals heterozygous for the Cys282Tyr haemochromatosis mutation. J Gastroenterol Hepatol 1999;14:1188-91.
33. Robinson JP, Johnson VL, Rogers PA, Houlston RS, Maher ER, Bishop DT, Evans DG, Thomas HJ, Tomlinson IP, Silver AR. Evidence for an association between compound heterozygosity for germ line mutations in the hemochromatosis (HFE) gene and increased risk of colorectal cancer. Cancer Epidemiol Biomarkers Prev 2005;14:1460-3.
34. Shaheen NJ, Silverman LM, Keku T, Lawrence LB, Rohlfs EM, Martin CF, Galanko J, Sandler RS. Association between hemochromatosis (HFE) gene mutation carrier status and the risk of colon cancer. J Natl Cancer Inst 2003;95:154-9.
35. Talseth BA, Meldrum C, Suchy J, Kurzawski G, Lubinski J, Scott RJ. Age of diagnosis of colorectal cancer in HNPCC patients is more complex than that predicted by R72P polymorphism in TP53. Int J Cancer 2006;118:2479-84.
36. Raszeja-Wyszomirska J, Kurzawski G, Suchy J, Zawada I, Lubinski J, Milkiewicz P. Frequency of mutations related to hereditary haemochromatosis in northwestern Poland. J Appl Genet 2008;49:105-7.
37. Barton JC, Acton RT, Lovato L, Speechley MR, McLaren CE, Harris EL, Reboussin DM, Adams PC, Dawkins FW, Gordeuk VR, Walker AP. Initial screening transferrin saturation values, serum ferritin concentrations, and HFE genotypes in Native Americans and whites in the hemochromatosis and iron overload screening study. Clin Genet 2006;69:48-57.
38. Goodall EF, Greenway MJ, van Marion I, Carroll CB, Hardiman O, Morrison KE. Association of the H63D polymorphism in the hemochromatosis gene with sporadic ALS. Neurology 2005;65:934-7.
39. Sutedja NA, Sinke RJ, Van Vught PW, Van der Linden MW, Wokke JH, Van Duijn CM, Njajou OT, Van der Schouw YT, Veldink JH, Van den Berg LH. The association between H63D mutations in HFE and amyotrophic lateral sclerosis in a Dutch population. Arch Neurol 2007;64:63-7.
40. Wang XS, Lee S, Simmons Z, Boyer P, Scott K, Liu W, Connor J. Increased incidence of the HFE mutation in amyotrophic lateral sclerosis and related cellular consequences. J Neurol Sci 2004;227:27-33.
41. Weinberg ED. Do some carriers of hemochromatosis gene mutations have higher than normal rates of disease and death? Biometals 2002;15:347-50.
42. Beutler E, Felitti VJ, Koziol JA, Ho NJ, Gelbart T. Penetrance of 845G -> A (C282Y) HFE hereditary haemochromatosis mutation in the USA. Lancet 2002;359:211-8.
43. Hunt JR, Zeng H. Iron absorption by heterozygous carriers of the HFE C282Y mutation associated with hemochromatosis. Am J Clin Nutr 2004;80:924-31.
44. Singh M, Ashwell M, Sanderson P, Cade J, Moreton J, Fairweather-Tait S, Roe M, Marx JJ, Worwood M, Cook JD. Risk of iron overload in carriers of genetic mutations associated with hereditary haemochromatosis: UK food standards agency workshop. Br J Nutr 2006;96:770-3.
45. Pietrangelo A. Hereditary hemochromatosis. Biochim Biophys Acta 2006;1763:700-10.
46. Parc Y, Boisson C, Thomas G, Olschwang S. Cancer risk in 348 French MSH2 or MLH1 gene carriers. J Med Genet 2003;40:208-13.
47. Ayonrinde OT, Milward EA, Chua ACG, Trinder D, Olynyk JK. Clinical perspectives on hereditary hemochomatosis. Crit Rev Clin Lab Sci 2008;45:451-84.